Phathom Pharmaceuticals, Inc.

NASDAQ•PHAT

CEO: Ms. Terrie J. Curran

セクター: Healthcare

業種: Biotechnology

上場日: 2019-10-25

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

連絡先情報

100 Campus Drive, Suite 102, Florham Park, NJ, 07932, United States

877-742-8466

www.phathompharma.com

時価総額

$854.97M

PER (TTM)

-3.6

17.2

配当利回り

52週高値

$18.31

52週安値

$2.21

52週レンジ

54%

順位65Top 96.0%

1.6

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

弱い • 1.6 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q4 2025 データ

売上高

$57.58M+0.00%

直近4四半期の推移

EPS

-$0.29+0.00%

直近4四半期の推移

フリーCF

-$4.89M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Strong Product Revenue Growth Product revenue reached $175.1M USD in 2025, reflecting a substantial 217.1% increase over 2024 sales.

Net Loss Significantly Narrowed Net loss decreased to $221.2M USD in 2025, showing $113.1M improvement versus prior year operating results.

Commercial Adoption Metrics Over 1.1 million VOQUEZNA prescriptions filled since launch; commercial coverage now exceeds 80% of US lives.

Long-Term Exclusivity Secured NCE exclusivity for all three VOQUEZNA products is secured, extending protection through May 3, 2032.

リスク要因

High Cash Burn Rate Operating cash usage totaled $166.8M USD in 2025; future capital needs remain uncertain despite recent financing.

Reliance on Single Product Entire revenue stream currently depends entirely on successful US commercialization of VOQUEZNA products for GERD and H. pylori.

Third-Party Manufacturing Dependence Reliance on Evonik, Catalent, and Sandoz for supply increases risk of disruption to commercial and clinical product availability.

Intellectual Property Uncertainty Patent scope and enforceability are uncertain; potential challenges could limit competitive advantage from licensed technology.

見通し

Targeting Operating Profitability Expect operating profitability beginning in the third quarter of 2026, excluding non-cash stock-based compensation expenses.

Pipeline Expansion Underway Initiated Phase 2 clinical trial evaluating vonoprazan for Eosinophilic Esophagitis (EoE) treatment in Q4 2025.

Geographic Market Evaluation Actively evaluating potential for vonoprazan expansion into European and Canadian markets for future growth opportunities.

Cost Reduction Measures Implemented organizational restructuring in May 2025 to reduce cash burn and focus resources on core commercial execution.

同業比較

売上高 (TTM)

IOVA

$263.50M

+60.6%

ANAB

$234.60M

+157.0%

MRVI

$185.74M

-28.3%

粗利益率 (最新四半期)

VIR

672.1%

-54902.1pp

IOVA

215.9%

+65.9pp

ANAB

199.8%

+99.5pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
ANAB	$1.93B	-141.3	1813.8%	79.8%
OCS	$1.54B	-12.0	-62.5%	1.0%
NRIX	$1.34B	-5.6	-57.5%	8.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

26.4%

高成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年4月29日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし